Annual MRI screenings starting at ages 30 to 35 may reduce breast-cancer mortality by more than 50% among women who carry certain genetic changes in three genes, according to a comparative modeling analysis. The predictions involve pathogenic variants in ATM, CHEK2 and PALB2 genes — which collectively are as prevalent as the much-reported BRCA1/2 gene mutations.